Gastrointestinal Cancer

Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.

Michael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.

The FDA has approved zenocutuzumab for the treatment of adult patients with NRG1 fusion–positive advanced, unresectable, or metastatic CCA.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Phase 1/2 data showed an ORR of 35% with daraxonrasib in second-line RAS G12-mutated pancreatic ductal adenocarcinoma.

Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.

Shubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

A one-stop-shop for regulatory updates across GI malignancies from the past month.

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

The FDA has permitted expanded access to daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A preclinical study reveals that impaired functioning of 2 enzymes contributes to the development and progression of precancerous lesions in the pancreas.

Peter Enzinger, MD, discusses diagnostic pathways, the role of surgery, and ongoing trials of interest in esophageal cancer in this clinician-focused FAQ.

The investigational pan-RAS inhibitor generated robust responses across 2 phase 1 dose-escalation studies that numerically exceeded historical benchmarks.

Tovecimig plus paclitaxel improved PFS vs paclitaxel alone in COMPANION-002, though crossover effects complicated OS outcomes.

The agency has set a target action date of August 25, 2026, for the sBLA, which is supported by data from the phase 3 HERIZON-GEA-01 trial.

The top 5 OncLive TV videos of the week cover insights in head and neck cancer, esophageal cancer, renal cell carcinoma, and breast cancer.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Peter C. Enzinger, MD, discusses the significance of Claudin 18.2 and HER2 as actionable biomarkers in gastroesophageal cancer.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

An sBLA seeking the approval of zenocutuzumab has been submitted to the FDA, and the agent was added to the NCCN guidelines for NRG1-positive cholangiocarcinoma.